๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A prospective study of tardive dyskinesia in Japan

โœ Scribed by T. Inada; K. Ohnishi; M. Kamisada; G. Matsuda; O. Tajima; Y. Yanagisawa; K. Hashiguchi; S. Shima; Y. Oh-e; Y. Masuda; T. Chiba; K. Kamijima; R. W. Rockhold; G. Yagi

Publisher
Springer-Verlag
Year
1991
Tongue
English
Weight
529 KB
Volume
240
Category
Article
ISSN
1433-8491

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Ineffectiveness of deanol in tardive dys
Ineffectiveness of deanol in tardive dyskinesia: A placebo controlled study
โœ C. Montigny; G. Chouinard; L. Annable ๐Ÿ“‚ Article ๐Ÿ“… 1979 ๐Ÿ› Springer ๐ŸŒ English โš– 536 KB

In a double-blind placebo-controlled study, deanol acetamidobenzoate, administered in doses up to 1.5 g q.d. for three weeks to chronic schizophrenic patients presenting moderate to severe tardive dyskinesia, failed to alleviate the dyskinetic movements. However, there was a tendency for a significa

Levetiracetam in tardive dyskinesia: An
Levetiracetam in tardive dyskinesia: An open label study
โœ Spiros Konitsiotis; Sofia Pappa; Christos Mantas; Venos Mavreas ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 53 KB ๐Ÿ‘ 2 views

Levetiracetam (LEV), a novel antiepileptic drug, has demonstrated antidyskinetic effect in preclinical animal models of Parkinson's disease (PD) and in one open label study in PD patients with levodopa-induced dyskinesia. The acute antidyskinetic effects of LEV in patients with tardive dyskinesia we

A pilot study of verapamil in the treatm
A pilot study of verapamil in the treatment of tardive dyskinesia
โœ Timothy G. Dinan; Claire Capstick ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 237 KB ๐Ÿ‘ 1 views

Six patients with severe and stable tardive dyskinesia were treated with verapamil, a calcium channel blocker, in doses ranging from 240 to 400 mg/day. Weekly assessments were made using the Simpson tardive dyskinesia rating scale. Neuroleptic medication was held constant during the 3-month baseline

Serotonin precursor effects in tardive d
Serotonin precursor effects in tardive dyskinesia
โœ Henry A. Nasrallah; Robert E. Smith; Frederick J. Dunner; Mona McCalley-Whitters ๐Ÿ“‚ Article ๐Ÿ“… 1982 ๐Ÿ› Springer ๐ŸŒ English โš– 208 KB

In an attempt to determine the role of serotoninergic mechanisms in the pathophysiology of tardive dyskinesia, the serotonin precursor 5-hydroxytryptophan (5 HTP) with carbidopa, a peripheral decarboxylase inhibitor, were given in a double-blind crossover design to seven patients with longstanding t